Targeting PDL1 with immune checkpoint inhibitors has shown to be a helpful strategy for enhancing the effector function of anti-tumor T cells in addition to disrupting the PD-1 immune checkpoint pathway by blocking PD-1 receptors on T lymphocytes. The gene discussed is PDCD1; the disease is neoplasm.